Mabion S.A.

Mabion S.A. is the first Polish biotechnology company and the only one in the country that has the innovation among its achievements. It was established in March 2007. On the basis of the Company’s creation laid the idea of initiating activities in the area of the economy founded on knowledge and technology. Mabion is based on the concept of combination of the latest achievements in science, research, technological and analytical projects management and implementation of the innovative management involving integration of science, technological and managerial knowledge.The core business is the development and implementation of the latest generation of biotech drugs based on monoclonal antibody technology.This therapeutic class is today a foundation to combat the most serious diseases thanks to two unique features - the specificity and safety.These drugs have the ability to recognize a cancer causing factor and to interact selectively only with it. This feature fits in with the concept of targeted therapies, in line with the global trend of personalized medicine.Another benefit to the patient is an extremely low toxicity of the therapy. It is obtained through a proper engineering of the drug’s structure, resembling the molecule of a patient's organism. As a result, the immune system treats the antibody protein as its own.